In this study, we confirmed that both 64Cu-cudotadipep and 64Cu-cunotadipep, which are newly developed PSMA-targeted radiopharmaceuticals, accumulate in PSMA-expressing prostate cancer cells. The gene discussed is FOLH1; the disease is prostate cancer.